Global POC Coag Test Market Driven by Increasing Geriatrics
By LabMedica International staff writers Posted on 03 May 2018 |
The global point-of-care (POC) coagulation testing market is projected to grow at a CAGR of over 6% during the period 2018-2022, driven by the growing geriatric population, worldwide, and increasing focus on personalized medicine. These are the latest findings of Technavio Research, (London, UK), a global technology research and advisory company.
The aging population is increasing gradually across the world. In 2015, people over the age of 65 years comprised about 7-8% of the global population and are estimated to grow by 50-55% with 1.2-1.4 billion people likely to be aged above 65 years by 2030. This increase in the aging population is leading to the rising prevalence of lung disease, stroke, and cancer among people over the age of 65 years as their immune systems and functioning of organs become weaker and more susceptible to infections. This is driving an increase in the number of blood coagulation disorders, thereby propelling the demand for blood coagulation testing and POC coagulation analyzers.
Additionally, the development of whole genome technology, increasing number of retail clinics, and companion diagnostics are driving the demand for personalized medicine. The increasing focus on personalized medicine is expected to positively impact the POC coagulation testing market as the determination of coagulation in blood for providing the profiles of individual patients is crucial for developing personalized medicine. Hence, the demand for diagnostic instruments such as POC coagulation analyzers is increasing as they are used to diagnose and decide the appropriate treatments required for the disease.
Based on end-user, the hospitals and clinics segment accounted for the largest market share of more than 74% in 2017 and is expected to continue dominating the POC coagulation testing market during the forecast period. Geographically, the Americas led the global POC coagulation testing market in 2017 with the largest share of over 54%, followed by the EMEA and Asia Pacific. However, the Asia Pacific region will account for the largest market share during the forecast period, while the Americas and the EMEA will witness a slight decline in their market share over the same period.
Related Links:
Technavio Research
The aging population is increasing gradually across the world. In 2015, people over the age of 65 years comprised about 7-8% of the global population and are estimated to grow by 50-55% with 1.2-1.4 billion people likely to be aged above 65 years by 2030. This increase in the aging population is leading to the rising prevalence of lung disease, stroke, and cancer among people over the age of 65 years as their immune systems and functioning of organs become weaker and more susceptible to infections. This is driving an increase in the number of blood coagulation disorders, thereby propelling the demand for blood coagulation testing and POC coagulation analyzers.
Additionally, the development of whole genome technology, increasing number of retail clinics, and companion diagnostics are driving the demand for personalized medicine. The increasing focus on personalized medicine is expected to positively impact the POC coagulation testing market as the determination of coagulation in blood for providing the profiles of individual patients is crucial for developing personalized medicine. Hence, the demand for diagnostic instruments such as POC coagulation analyzers is increasing as they are used to diagnose and decide the appropriate treatments required for the disease.
Based on end-user, the hospitals and clinics segment accounted for the largest market share of more than 74% in 2017 and is expected to continue dominating the POC coagulation testing market during the forecast period. Geographically, the Americas led the global POC coagulation testing market in 2017 with the largest share of over 54%, followed by the EMEA and Asia Pacific. However, the Asia Pacific region will account for the largest market share during the forecast period, while the Americas and the EMEA will witness a slight decline in their market share over the same period.
Related Links:
Technavio Research
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus